Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTI-03 in Recently Diagnosed IPF
NCT05954988Phase 1Completed
- Sponsor
- Rein Therapeutics
- Start
- Jul 2023
- Primary completion
- Sep 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Rein Therapeutics. Primary endpoint: Incidence of Treatment-emergent Adverse Events at 21 days. Started Jul 2023; status: completed.
02
Drugs
LTI-03
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05954988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954988.